(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
10 July 2008 (10.07.2008)

PCT

(10) International Publication Number
WO 2008/083174 A3

(51) International Patent Classification:
C07K 16/28 (2006.01) *A61K 31/14* (2006.01)
A61K 39/395 (2006.01) *A61K 31/18* (2006.01)
A61K 39/12 (2006.01) *A61K 31/20* (2006.01)

(21) International Application Number:
PCT/US2007/088851

(22) International Filing Date:
26 December 2007 (26.12.2007)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/877,518 27 December 2006 (27.12.2006) US

(71) Applicants *(for all designated States except US)*: **EMORY UNIVERSITY** [US/US]; Fourth Floor, MS 1599-001-1AZ, 1599 Clifton Road, NE, Atlanta, GA 30322 (US). **DANA-FARBER CANCER INSTITUTE** [US/US]; 44 Binney Street, Boston, MA 02115-6084 (US). **PRESIDENT AND FELLOWS OF HARVARD COLLEGE** [US/US]; 17 Quincy Street, Cambridge, MA 02138 (US).

(72) Inventors; and
(75) Inventors/Applicants *(for US only)*: **AHMED, Rafi** [US/US]; 1811 Durand Mill Drive, Atlanta, GA 30307 (US). **AMARA, Rama** [IN/US]; 785 Houston Mill Road, Unit 1, Atlanta, GA 30329 (US). **FREEMAN, Gordon** [US/US]; 305 Walnut Street, Brookline, MA 02445 (US). **SHARPE, Arlene** [US/US]; 305 Walnut Street, Brookline, MA 02445 (US).

(74) Agent: **SIEGEL, Susan, Alpert**; Klarquist Sparkman, LLP, One World Trade Center, Suite 1600, 121 SW Salmon Street, Portland, OR 97204 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declaration under Rule 4.17:
— *of inventorship (Rule 4.17(iv))*

Published:
— *with international search report*
— *with sequence listing part of description published separately in electronic form and available upon request from the International Bureau*

(88) Date of publication of the international search report:
18 December 2008

(54) Title: COMPOSITIONS AND METHODS FOR THE TREATMENT OF INFECTIONS AND TUMORS

(57) Abstract: PD-1 antagonists are disclosed that can be used to reduce the expression or activity of PD-1 in a subject. An immune response specific to an infectious agent or to tumor cells can be enhanced using these PD- 1 antagonists in conjunction with an antigen from the infectious agent or tumor. Thus, subjects with infections, such as persistent infections can be treated using PD-1 antagonists. In addition, subjects with tumors can be treated using the PD-1 antagonists. In several examples, subjects can be treated by transplanting a therapeutically effective amount of activated T cells that recognize an antigen of interest and by administering a therapeutically effective amount of a PD-1 antagonist.

WO 2008/083174 A3